Adipose-Derived Regenerative Cells Promote Tendon-Bone Healing in a Rabbit Model

著者	小坂 正裕
著者別表示	Kosaka Masahiro
journal or publication title	博士論文本文Full
学位授与番号	13301甲第4343号
学位名	博士（医学）
学位授与年月日	2016-03-22
URL	http://hdl.handle.net/2297/45623

doi: <https://doi.org/10.1016/j.arthro.2015.10.012>

1 **Title:**

2 **Adipose-Derived Regenerative Cells Promote Tendon-Bone Healing in a Rabbit Model**

3

Abstract

Purpose: To evaluate the therapeutic effect of adipose-derived regenerative cell (ADRC) administration on tendon-bone healing in a rabbit ACL reconstruction model.

Methods: Anterior cruciate ligament (ACL) reconstruction with semitendinosus tendon autograft was performed on the right knees of adult white rabbits. Eighty rabbits were divided into 2 groups: a treatment group, in which the graft was coated with ADRCs mixed in fibrin glue carrier during surgery, and a control group, in which the graft was coated with fibrin glue only. At 2, 4, 6, 8, and 12 weeks postoperatively, 8 rabbits were sacrificed in each group. Three were used for histological evaluation at the tendon-bone interface, and 5 for biomechanical examination.

Results: In histological analysis, chondroid cells appeared more orderly and more regular in size and shape, and Sharpey-like fibers, which connected the tendon graft and bone tissue, appeared earlier in ADRC-treated tissues than in control tissues. In biomechanical analysis, the ultimate failure load in the ADRC-treated group was significantly greater than that in the control group at 2 and 4 weeks (29.5 ± 7.2 N vs. 20.9 ± 2.7 N; $P = .016$ and 32.3 ± 3.9 N vs. 22.8 ± 5.4 N; $P = .016$, respectively). Stiffness was significantly higher in the ADRC-treated group than in the control group at 6 weeks (21.7 ± 5.9 N/mm vs. 12.6 ± 4.9 N/mm; $P = .037$). Although the ultimate failure load and stiffness of the ADRC-treated limb was higher than that of the limb in the control group at 8 and 12 weeks, these differences were not significant.

Conclusions: Local administration of ADRCs promoted the early healing process at the tendon-bone junction, both histologically and mechanically, in the rabbit ACL reconstruction model.

Clinical Relevance: ADRCs could be used to enhance graft healing in ACL reconstruction.

27 **Introduction**

28

29 Autologous tendon grafts are currently popular for anterior cruciate ligament (ACL) reconstruction.
30 Secure healing between tendon and bone is necessary for successful ACL reconstruction. However,
31 tendon-bone healing occurs slowly, which can limit early return to sports activities. Several studies
32 have shown that tendon-bone healing occurs more slowly than bone-to-bone healing,¹⁻³ which raises
33 concerns regarding the adhesive strength between tendon graft and bone tunnels and the
34 subsequent risk of graft failure. Interventions that can improve and accelerate tendon-bone healing
35 could potentially reduce the rate of graft failure and allow for early aggressive rehabilitation.

36

37 Adipose tissue has been gaining attention as a promising source of undifferentiated mesenchymal
38 stem cells. Adipose-derived regenerative cells (ADRCs) have multilineage potential equivalent to
39 bone marrow-derived stem cells and can be easily obtained in large amounts from subcutaneous
40 adipose tissue without the need for culture and expansion.^{4,5} Although a number of reports have
41 been published regarding clinical applications of ADRCs,⁶⁻¹⁶ we are unaware of any study
42 investigating ADRCs for their potential benefit in enhancing tendon graft healing in a bone tunnel.
43 The aim of this study was to evaluate the therapeutic effect of ADRC administration on
44 tendon-bone healing in a rabbit ACL reconstruction model. We hypothesized that ADRC
45 administration at the tendon-bone interface may promote the healing between tendon graft and
46 bone tunnel.

47

48 **Methods**

49

50 **Experimental Design**

51 Eighty-two female Japanese white rabbits (age, 15-17 weeks) weighing between 3.0 and 3.5 kg were
52 used in this study. Because of the unified standards, we integrated the sex of the animals. We did
53 not especially mean anything by selecting female rabbits. ACL reconstruction with a
54 semitendinosus tendon autograft was performed on the right knee. Eighty animals were randomly
55 divided into 2 groups, and the remaining 2 were used for tracing of ADRCs. In the treatment group,
56 the graft was coated with ADRCs mixed in fibrin glue carrier during surgery. In the control group,
57 the graft was coated with fibrin glue only. The animals in both groups were divided into five
58 subgroups and killed at 2, 4, 6, 8, and 12 weeks postoperatively; thus, 8 animals per group were
59 sacrificed at each time point after surgery, at which time femur-graft-tibia complexes were
60 harvested for histological and biomechanical evaluations. In all subgroups, 5 of the 8 rabbits were
61 used for biomechanical evaluation, and the remaining 3 were used for histological observation. The
62 animal experiments were conducted with the approval of the Institutional Animal Care and Use
63 Committee and carried out in strict accordance with its regulations.

64

65 **ADRC Preparation**

66 ADRCs were isolated by modifying a previously established method.^{17,18} Adipose tissue (1.5 g) of
67 female rabbits that were not included in the study was harvested from the adipose tissue pouch on
68 the interscapular region located along the dorsomedial line, nearly 5 cm from the skull in the
69 craniocaudal direction, and then washed with phosphate-buffered saline (PBS, Wako, Osaka,
70 Japan). The tissue was cut into strips over a period of 5 min. Collagenase (Wako) was dissolved in
71 PBS for a concentration of 0.12% in 20 ml and used to digest adipose tissue at 37°C for 45 min in a
72 water bath. The mixture was shaken every 15 min during the digestion period. Immediately after
73 the reaction was completed, 20 mL of Dulbecco's modified Eagle's medium (DMEM, Wako) was
74 added, and collagenase activity was neutralized. The resulting solution was filtered. The filtrate

was centrifuged at 1300 rpm for 6 min at 25°C, and the supernatant was removed. The pellet of ADRCs was subsequently administered at the tendon-bone junction. Approximately 1×10^5 cells were included in this pellet.

Surgical Procedure

Surgery was performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). The animals were operated on under general anesthesia with subcutaneous injection of xylazine (5 mg/kg body weight; Bayer, Tokyo, Japan), and sedation was maintained by intravenous injection of 2.5% sodium phenobarbital (Kyoritsu Pharmaceutical, Tokyo, Japan). Using an aseptic technique, we approached the right knee joint through a medial parapatellar incision. The semitendinosus tendon was identified and transected at its musculotendinous junction, and the graft was prepared by removing the attached muscle and passing the holding sutures through each end of the tendon graft. The original ACL was resected, and then tunnels (2.0 mm in diameter) were drilled in the lateral femoral condyle and the medial aspect of the tibia at the footprint of the original ACL. The graft was routed through the tunnels, and then the previously mentioned materials were injected onto the interface between the grafted tendon and the bone tunnel. In the ADRC group, 0.2 ml of fibrin glue containing ADRCs was injected. On the other hand, in the control group, an equal amount of fibrin glue only was injected onto the interface. In the 2 animals used for tracing of ADRCs, the equal amount of fibrin glue containing ADRCs labeled with 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI) was injected. After the injection, both graft ends were secured under tension to the neighboring soft tissue with 2-0 Ethibond suture (Ethicon, Somerville, New Jersey). The incision was closed at each layer in a standard fashion. Postoperatively, the limbs were not immobilized, and the animals were allowed normal activity in individual cages. At each time point after surgery, the animals were sacrificed with an overdose of intravenous pentobarbital after general anesthesia.

102 **Histological Evaluation**

103 At the time the animals were killed, the entire joint including the femoral and tibial bone tunnels
104 was harvested. For histological observation, tissues were fixed in 10% formalin, and conventional
105 paraffin-embedded sections were prepared. The samples were cut into 5- μ m-thick sections
106 longitudinal to the bone tunnels in the femur and tibia and stained with hematoxylin and eosin
107 (H&E) for the examination of healing at the interface between the tendon graft and bone tunnel
108 under light microscopy. Bone-tendon healing was graded in a semiquantitative manner with a scale
109 from 0 (worst) to 8 (best) using a modified version of the histological scoring system of Nakase et
110 al.¹⁹ based on new tissue formation at the interface and graft remodeling (Table 1). The two sections
111 of each specimen were graded by two investigators (J.N., K.H.) in a blinded fashion, and the mean
112 histologic scores of the two observers were determined as the final results to minimize sampling
113 error and misinterpretation.

114

115 **ADRC Labeling**

116 In the 2 animals used for tracing of ADRCs, cells were labeled with DiI (Vybrant® DiI Cell Labeling
117 Solution; Life Technologies, Carlsbad, CA, USA) and transplanted to confirm the survival potential
118 and location of transplanted ADRCs. DiI binds to cellular thiols and has long-term stability, which
119 enables the tracing of DiI-labeled transplanted cells in the host tissue. Two weeks after injection of
120 labeled cells, the rabbits were euthanized, and frozen sections were prepared in the longitudinal
121 plane. The presence of DiI-labeled cells in the bone tunnel was then observed using a fluorescence
122 microscope.

123

124 **Biomechanical Evaluation**

125 At the time of each animal's death, the femur and tibia were sectioned 5 cm from the knee joint. In
126 addition, 5 knees of normal rabbits were evaluated to obtain the structural biomechanical
127 properties with intact ACLs. All soft tissues around the knee were carefully removed except for the
128 tendon graft connecting the 2 bones. The suture material used to secure the grafts during surgery

129 was also disturbed. Each specimen was stored at -80°C until testing. Before mechanical testing,
130 each knee was thawed overnight at 4°C. The femur and tibia were separately mounted in
131 cylindrical aluminum tubes using polymethylmethacrylate resin. During all preparations and
132 testing, specimens were kept moist with saline spray. These samples were mounted on an
133 electromechanical testing machine (Legacy 4482, Instron, Kanagawa, Japan), and all mechanical
134 testing was conducted by one investigator (M.K.). Each femur-graft-tibia complex was mounted in a
135 custom jig to ensure that the tensile load could be applied along the longitudinal axis of both the
136 femoral and tibial tunnels. The femur-graft-tibia complex was applied with a preload of 1 N for 30
137 seconds, and the specimen was cycled 5 times between elongation limits of 0 and 0.75 mm at a rate
138 of 2 mm/min. A tensile force was applied at a constant elongation rate of 20 mm/min. The ultimate
139 load at the point of failure was recorded. The stiffness was calculated from the slope of the linear
140 region of the load-displacement curve. Furthermore, the site of failure, either by pullout of the
141 tunnel or midsubstance graft rupture, was determined by gross examination.

142

143 **Statistical Analysis**

144 The semiquantitative histological scores, mean ultimate failure load, and stiffness between
145 treatment and control groups were compared using the Mann-Whitney U test. The inter-observer
146 reliability was assessed by kappa (κ) statistic, and agreement in percentage was calculated. The
147 Mann-Whitney U test was also used for the comparison of biomechanical properties at different
148 time points within each group. The failure patterns of the femur-graft-tibia complex shown by the
149 biomechanical testing were analyzed with the Fisher exact test. Differences were considered
150 statistically significant at $P < .05$.

151

152 **Results**

153

154 In this study, except minor redness and swelling at the reconstructed knee, there were no
155 premature deaths, nor were there any serious joint infections on postmortem examination of the
156 knees. All of the animals were euthanized at the planned times.

157

158 **Histological Analysis**

159 The adhesion of tendon to bone was analyzed histologically during the 12 weeks after treatment. At
160 2 weeks after surgery, in the control group, light microscopic examination revealed inflammatory
161 response around the autografts and a highly cellular, vascular, and fibrous tissue infiltrating the
162 interface (Fig 1A). Poorly organized and sparse collagen fibers appeared at the interface of the bone
163 and the tendon graft. At 2 weeks in the ADRC-treated group, fibrovascular tissue appeared better
164 organized, and cartilaginous tissue had appeared (Fig 1B). At 4 weeks, loose connective tissue
165 characterized by directionally arranged collagen fibers was seen in fibrovascular tissue, and large
166 areas of fairly disorganized cartilaginous tissue were observed around the tendon-bone interface in
167 the control group (Fig 1C). In the ADRC-treated group, the fibrovascular interface tissue became
168 denser and better organized, and occasionally Sharpey-like fibers, which connected the tendon graft
169 and bone tissue, appeared. In addition, the chondroid cells appeared more regular in size and shape,
170 with more orderly laying down of chondro-osteoid matrix (Fig 1D). At 6 weeks, the area between
171 tendon and bone was seen to become more mature, with the fibrous connective tissue and
172 narrowing of the distance between the tendon and bone in both groups (Fig 1E,F). The chondroid
173 cells were closely associated with surrounding tendon and bone, and fibrocartilaginous tissue was
174 seen to gradually blend into the tendon substance especially in the ADRC-treated group (Fig 1F). At
175 8 weeks, the interface area between tendon and bone was still a distinct entity, although it was
176 definitely narrower in both groups (Fig 1G,H). The interface was more organized and mature in the
177 ADRC-treated group (Fig 1H). At 12 weeks, gradual blending of fibrocartilaginous tissue into the
178 tendon substance and occasionally mineralized fibrocartilaginous tissue appeared in the control

group (Fig 1I). In the ADRC-treated group, a gradual and smooth transition was seen from bone to mineralized fibrocartilaginous tissue, fibrocartilaginous tissue, and finally tendon (Fig 1J). Bone-tendon healing was graded in a previously described manner, and the score of both groups increased with time. For example, in one case histological appearance was scored 2 (1 based on graft remodeling and 1 based on new tissue formation at the interface) at 2 weeks (Fig 1A), and scored 6 (2 based on graft remodeling and 4 based on new tissue formation at the interface) at 8 weeks (Fig 1G). The semiquantitative score of tendon-bone healing quality was significantly higher in the ADRC-treated group than in the control group at 2, 4, and 6 weeks postoperatively (all $P < .05$) (Table 2). The percentage of agreement and κ for inter-observer reliability were 78.3 and 0.737, respectively.

189

ADRC Labeling

The distribution of DiI-positive (red) areas was detected at 2 weeks after transplantation (Fig. 2). DiI labeling suggested that the transplanted cells had survived and were localized to the site where they were transplanted at 2 weeks post-transplantation. The transplanted cells survived up to at least 2 weeks after transplantation, with some cells being focally distributed in the bone tunnel.

195

Biomechanical Analysis

Fifty limbs were analyzed after ACL reconstruction. The ultimate failure load of the 2 groups increased with time. The ADRC-treated limb generally had a greater failure load than the limb in the control group. There were significant increases between the ADRC-treated group and the control group at 2 weeks (29.5 ± 7.2 N and 20.9 ± 2.7 N, respectively; $P = .016$) and 4 weeks (32.3 ± 3.9 N and 22.8 ± 5.4 N, respectively; $P = .016$). Although the ultimate failure load of the ADRC-treated limb was higher than that of the limb in the control group at 6 weeks (34.2 ± 5.3 N and 26.6 ± 5.9 N, respectively; $P = .076$), 8 weeks (43.7 ± 17.5 N and 36.5 ± 15.1 N, respectively; $P = .076$), and 12 weeks (61.0 ± 18.5 N and 57.2 ± 12.5 N, respectively; $P = .754$), the difference was

not significant (Fig 3). The within-group analysis showed significant differences between 2 weeks and 12 weeks, 4 weeks and 12 weeks, and 6 weeks and 12 weeks in the ADRC-treated group, and between 2 weeks and 8 weeks, 2 weeks and 12 weeks, 4 weeks and 8 weeks, 4 weeks and 12 weeks, 6 weeks and 12 weeks, and 8 weeks and 12 weeks in the control group ($P = .016$, $P = .016$, $P = .016$, $P = .009$, $P = .009$, $P = .016$, $P = .009$, $P = .009$ and $P = .047$, respectively). The ultimate failure loads of the limbs in both ACL reconstructed groups were much weaker than those of intact ACLs (273.1 ± 27.3 N) ($P < .001$).

The stiffness in the ADRC-treated group was significantly higher than that in the control group at 6 weeks (21.7 ± 5.9 N/mm and 12.6 ± 4.9 N/mm, respectively; $P = .037$). There were no significant differences in stiffness between the groups at 2 weeks (15.4 ± 8.1 N/mm and 11.5 ± 2.9 N/mm, respectively; $P = .465$), 4 weeks (17.2 ± 8.0 N/mm and 13.9 ± 5.6 N/mm, respectively; $P = .917$), 8 weeks (23.3 ± 13.6 N/mm and 17.3 ± 12.3 N/mm, respectively; $P = .076$), and 12 weeks (30.2 ± 12.7 N/mm and 26.8 ± 11.1 N/mm, respectively; $P = .917$) (Fig 4). The within-group analysis showed significant differences between 2 weeks and 12 weeks in the ADRC-treated group, and between 2 weeks and 8 weeks, 2 weeks and 12 weeks, and 6 weeks and 12 weeks in the control group ($P = .047$, $P = .046$, $P = .047$ and $P = .047$, respectively).

At 2 and 4 weeks, all tendons were pulled away from the bone tunnel at the failure point. At 6 weeks, 1 of the 5 ADRC-treated limbs failed by rupture in the midsubstance of the tendon, while all of the control limbs failed by tendon pullout from the bone tunnel. At 8 weeks, 1 each of the 5 ADRC-treated limbs and control limbs failed by rupture in the midsubstance. At 12 weeks, 3 of 5 ADRC-treated limbs and 2 of 5 control limbs failed by rupture in the midsubstance. Fisher exact test showed no significant difference between the rates of pullout in the ADRC-treated and control limbs in each time point and overall.

231 Discussion

232

233 This study demonstrated that local administration of ADRCs has the potential to promote healing
234 at the tendon-bone interface, both histologically and mechanically, in a rabbit model of ACL
235 reconstruction. Histological maturation occurred earlier, and the semiquantitative score of
236 tendon-bone healing quality at 2, 4, and 6 weeks postoperatively was significantly higher in
237 ADRC-treated tissues than in control tissues. Biomechanical properties were significantly better in
238 the ADRC-treated group than the control group at 2 and 4 weeks after surgery in terms of the
239 ultimate failure load.

240

241 Several investigators have demonstrated positive effects of stem cells on tendon-bone healing. Lim
242 et al.²⁰ reported that coating of tendon grafts with mesenchymal stem cells (MSCs) in ACL
243 reconstruction promoted healing by the formation of an intervening zone of cartilage resembling the
244 chondral enthesis of the normal ACL insertion. They also found that MSC-enhanced
245 reconstructions demonstrated significantly higher failure load and stiffness than controls on
246 biomechanical tests in rabbits. Similarly, Soon et al.²¹ reported that MSCs applied at the
247 tendon-bone interface during ACL reconstruction resulted in the development of an intervening
248 zone of fibrocartilage and improvement in load-to-failure rates. Li et al.²² reported that bone
249 marrow mesenchymal stem cell (BMSC) transplantation to the tendon-bone interface was shown to
250 enhance its mechanical properties by promoting tendon-bone tunnel healing at early time points
251 4–8 weeks after ACL reconstruction. Mifune et al.²³ reported that ACL-derived stem cells
252 contributed to the tendon-bone healing after ACL reconstruction by enhancing angiogenesis and
253 osteogenesis, which in turn contributed to increasing biomechanical strength. Lui et al.²⁴ reported
254 that wrapping the ACL graft with a sheet of tendon-derived stem cells before graft insertion
255 promoted graft healing in the early stage after ACL reconstruction radiographically, histologically,
256 and biomechanically in a rat model.

257

258 These studies suggest that many types of stem cells can improve the tendon-bone healing process
259 and result in better mechanical properties. However, these agents also have drawbacks to clinical
260 use because of concerns such as donor site morbidity, limitation of the cell source, difficulty of
261 isolating stem cells, time and effort required for ex vivo culture of stem cells and formation of a cell
262 sheet if needed, possible side effects after transplantation in humans, and ethical considerations.

263

264 The stromal vascular fraction of adipose tissue contains a mixed, multipotent population of cells,
265 and a number of investigations have described the potential applications of adipose-derived stem
266 cells (ADSCs).^{4,5,17,18,25} ADRCs are the nonbuoyant cellular fraction containing several types of stem
267 and regenerative cells, including ADSCs, vessel-forming cells such as endothelial and smooth
268 muscle cells and their progenitors, and preadipocytes.²⁶ ADSCs and ADRCs could be used in
269 regenerative medicine in various conditions.⁶⁻¹⁶ According to an in vitro study, ADSCs, similar to
270 BMSCs, can differentiate into various cell types, including adipocytes, chondroblasts, endothelial
271 cells, fibroblasts, myoblasts, and osteoblasts.^{4,5,17,25,27} On the basis of both in vitro experiments and
272 preclinical studies, multiple reports have already been published regarding clinical applications of
273 ADSCs and ADRCs, including beneficial results of their use in breast reconstruction.^{6,7} There are
274 also reports of their use to treat ischemic cardiomyopathy,⁸ calvarial bone defects,⁹ enterocutaneous
275 fistulas in patients with Crohn's disease,¹⁰ and chronic ulcers caused by radiotherapy.¹¹ Recently,
276 various basic and applied studies on the use of ADSCs in the orthopaedic field also have been
277 conducted.¹²⁻¹⁶ In addition, ADSCs have immunosuppressive properties that can be used to control
278 graft-versus-host disease.²⁸

279

280 ADRCs have several advantages as a source of tissue stem cells that led us to focus on them in this
281 study. First, autologous ADRCs can be easily isolated in large amounts from abundant and
282 accessible subcutaneous adipose tissue. Furthermore, harvesting of ADRCs is less invasive than
283 that of BMSCs and other stem cells, and many more stem cells can be harvested at one time.²⁹
284 Adipose tissue yields approximately 500-fold more stem cells than the same amount of adult bone

marrow.^{4,27} In addition, as mentioned above, ADRCs have already been applied in various clinical fields. For the above reasons, we have considered ADRCs a potentially efficient source for clinical applications in promoting tendon-bone healing.

ADSCs have the ability not only to directly differentiate into some types of topical cells but also to indirectly facilitate the healing process by promoting the secretion of various humoral factors also called paracrine effects.^{30,31} In secretory protein analysis, ADSCs secrete significantly larger amounts of growth factors and inflammatory cytokines, such as vascular endothelial growth factor, hepatocyte growth factor, and interleukin 6, than BMSCs.³⁰ ADRCs contain ADSCs, vessel-forming cells such as endothelial and smooth muscle cells and progenitors, and preadipocytes.²⁶

Limitations

There are several limitations to this study. First, we chose to use a rabbit model of ACL reconstruction. This model has been validated in previous reports in the literature.^{3,20} However, studies using small-animal models of ACL reconstruction have inherent problems such as a wide range in biomechanical results, which was also seen in the present study.²⁰ In addition, the healing potential of small animals is different from that of humans. Therefore, the results obtained from this animal model cannot be assumed to be directly applicable to clinical settings. More accurate and reliable results may have been achieved with the use of a larger animal model. Second, we did not conduct a histological analysis of the intra-articular portion of the graft. Although this evaluation was not included as an aim of this study, remodeling of the graft midsubstance is also an important part of graft healing and could affect the results of biomechanical analysis. The failure patterns of the femur-graft-tibia complex shown by biomechanical testing changed from pullout from the bone tunnel to rupture in the midsubstance with time. This shift could be the result of changes in the histological features of the intra-articular graft. Third, the sample size in each group was relatively small, while we studied multiple time points and thus had information on changes over time. Although the blinded nature of this study avoids biases in the assessments, the small

sample size limits the statistical rigor of the findings and efficacy conclusions of the study. Future investigations with a larger sample size at specific time periods would increase the strength of this study for a more accurate evaluation of the effects of ADRCs on tendon-bone healing. Fourth, we did not identify the proper cell concentration in the pellet and its true contents. We calculated the number of cells in the pellet using a microscope, and our result was similar to the concentration assumed from previous studies. Additionally, ADRCs are known to contain ADSCs and several other types of cells and their progenitors, as mentioned above. However, for a stricter analysis, a rigorous analysis of the pellet is necessary using indirect methods, such as flow cytometry and indirect immunofluorescence of the pellet. In addition, we did not trace labeled ADRCs over a longer period, although we confirmed that the cells implanted with the fibrin glue infiltrated into the bone-tendon interface at 2 weeks after ACL reconstruction. We are thus unable to comment on whether the healing tissue at the tendon-bone junction originated from the ADRCs themselves or from cells recruited locally. Analysis of the fate of the ADRCs is the subject of a subsequent study by our group. Fifth, we did not have a group without fibrin glue. Shoemaker et al.³² had previously examined the effects of fibrin glue on the healing of tendons to bone tunnels in the proximal tibia in dogs. In the first 2 weeks after surgery, fibrin glue appeared to speed up the organization of the fibrovascular interface, but no histological differences were visible between the two groups with or without fibrin glue at 28 days. Although biomechanical evaluation was not performed in that experiment, we believe that using a fibrin glue carrier in both the treatment and control reconstructions did not appreciably influence the outcome of our results. Sixth, the histological findings presented in this study were mainly subjective and preliminary. More objective and precise quantitative methods are needed for more accurate evaluations. Molecular biological data or immunohistological examination may also be valuable for showing the underlying mechanisms by which ADRCs aid ACL reconstruction.

336

337 **Conclusions**

338 Local administration of ADRCs promoted the early healing process at the tendon-bone junction,

339 both histologically and mechanically, in the rabbit ACL reconstruction model.

340

341 REFERENCES

- 342 1. Kondo E, Yasuda K, Katsura T, Hayashi R, Kotani Y, Tohyama H. Biomechanical and
343 histological evaluations of the doubled semitendinosus tendon autograft after anterior cruciate
344 ligament reconstruction in sheep. *Am J Sports Med* 2012;40:315-324.
- 345 2. Ekdahl M, Nozaki M, Ferretti M, Tsai A, Smolinski P, Fu FH. The effect of tunnel placement on
346 bone-tendon healing in anterior cruciate ligament reconstruction in a goat model. *Am J Sports*
347 *Med* 2009;37:1522-1530.
- 348 3. Kanazawa T, Soejima T, Murakami H, Inoue T, Katouda M, Nagata K. An immunohistological
349 study of the integration at the bone-tendon interface after reconstruction of the anterior
350 cruciate ligament in rabbits. *J Bone Joint Surg Br* 2006;88:682-687.
- 351 4. De Ugarte DA, Morizono K, Elbarbary A, et al. Comparison of multi-lineage cells from human
352 adipose tissue and bone marrow. *Cells Tissues Organs* 2003;174:101-109.
- 353 5. Feng Z, Ting J, Alfonso Z, et al. Fresh and cryopreserved, uncultured adipose tissue-derived
354 stem and regenerative cells ameliorate ischemia-reperfusion-induced acute kidney injury.
355 *Nephrol Dial Transplant* 2010;25:3874-3884.
- 356 6. Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K. Cell-assisted lipotransfer for cosmetic
357 breast augmentation: Supportive use of adipose-derived stem/stromal cells. *Aesthetic Plast*
358 *Surg* 2008;32:48-55.
- 359 7. Yoshimura K, Asano Y, Aoi N, et al. Progenitor-enriched adipose tissue transplantation as
360 rescue for breast implant complications. *Breast J* 2010;16:169-175.
- 361 8. Perin EC, Sanz-Ruiz R, Sánchez PL, et al. Adipose-derived regenerative cells in patients with
362 ischemic cardiomyopathy: The PRECISE Trial. *Am Heart J* 2014;168:88-95.
- 363 9. Lendeckel S, Jödicke A, Christophis P, et al. Autologous stem cells (adipose) and fibrin glue
364 used to treat widespread traumatic calvarial defects: Case report. *J Craniomaxillofac Surg*
365 2004;32:370-373.
- 366 10. Garcia-Olmo D, Herreros D, Pascual M, et al. Treatment of enterocutaneous fistula in Crohn's
367 Disease with adipose-derived stem cells: A comparison of protocols with and without cell

expansion. *Int J Colorectal Dis* 2009;24:27-30.

11. Rigotti G, Marchi A, Galiè M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: A healing process mediated by adipose-derived adult stem cells. *Plast Reconstr Surg* 2007;119:1409-1424.

12. Zielins ER, Tevlin R, Hu MS, et al. Isolation and Enrichment of Human Adipose-derived Stromal Cells for Enhanced Osteogenesis. *J Vis Exp* 2015;12(95):52181.

13. Jang Y, Koh YG, Choi YJ, et al. Characterization of adipose tissue-derived stromal vascular fraction for clinical application to cartilage regeneration. *In Vitro Cell Dev Biol Anim* 2015;51:142-150.

14. Yin F, Cai J, Zen W, et al. Cartilage Regeneration of Adipose-Derived Stem Cells in the TGF- β 1-Immobilized PLGA-Gelatin Scaffold. *Stem Cell Rev* 2014 Oct 1. [Epub ahead of print]

15. Chen HS, Su YT, Chan TM, et al. Human adipose-derived stem cells accelerate the restoration of tensile strength of tendon and alleviate the progression of rotator cuff injury in rat model. *Cell Transplant* 2015;24:509-520.

16. Stanco D, Viganò M, Perucca Orfei C, et al. Multidifferentiation potential of human mesenchymal stem cells from adipose tissue and hamstring tendons for musculoskeletal cell-based therapy. *Regen Med* 2015 Jan 7:1-15. [Epub ahead of print]

17. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. *Tissue Eng* 2001;7:211-228.

18. Torres FC, Rodrigues CJ, Stocchero IN, Ferreira MC. Stem cells from the fat tissue of rabbits: An easy-to-find experimental source. *Aesthetic Plast Surg* 2007;31:574-578.

19. Nakase J, Kitaoka K, Matsumoto K, Tomita K. Facilitated tendon-bone healing by local delivery of recombinant hepatocyte growth factor in rabbits. *Arthroscopy* 2010;26:84-90.

20. Lim JK, Hui J, Li L, Thambyah A, Goh J, Lee EH. Enhancement of tendon graft osteointegration using mesenchymal stem cells in a rabbit model of anterior cruciate ligament reconstruction. *Arthroscopy* 2004;20:899-910.

21. Soon MY, Hassan A, Hui JH, Goh JC, Lee EH. An analysis of soft tissue allograft anterior

395 cruciate ligament reconstruction in a rabbit model: A short-term study of the use of
396 mesenchymal stem cells to enhance tendon osteointegration. *Am J Sports Med* 2007;35:962-971.

397 22. Li YG, Wei JN, Lu J, Wu XT, Teng GJ. Labeling and tracing of bone marrow mesenchymal stem
398 cells for tendon-to-bone tunnel healing. *Knee Surg Sports Traumatol Arthrosc*
399 2011;19:2153-2158.

400 23. Mifune Y1, Matsumoto T, Ota S, et al. Therapeutic potential of anterior cruciate
401 ligament-derived stem cells for anterior cruciate ligament reconstruction. *Cell Transplant*
402 2012;21:1651-1665.

403 24. Lui PP, Wong OT, Lee YW. Application of tendon-derived stem cell sheet for the promotion of
404 graft healing in anterior cruciate ligament reconstruction. *Am J Sports Med* 2014;42:681-689.

405 25. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. *Circ*
406 *Res* 2007;100:1249-1260.

407 26. Zhu M, Zhou Z, Chen Y, et al. Supplementation of fat grafts with adipose-derived regenerative
408 cells improves long-term graft retention. *Ann Plast Surg* 2010;64:222-228.

409 27. Fraser JK, Schreiber R, Strem B, et al. Plasticity of human adipose stem cells toward
410 endothelial cells and cardiomyocytes. *Nat Clin Pract Cardiovasc Med* 2006;3:S33-37.

411 28. Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose
412 tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable
413 for the control of the graft-versus-host disease. *Stem Cells* 2006;24:2582-2591.

414 29. Fraser JK, Zhu M, Wulur I, Alfonso Z. Adipose-derived stem cells. *Methods Mol Biol*
415 2008;449:59-67.

416 30. Nakanishi C, Nagaya N, Ohnishi S, et al. Gene and protein expression analysis of mesenchymal
417 stem cells derived from rat adipose tissue and bone marrow. *Circ J* 2011;75:2260-2268.

418 31. Suganuma S, Tada K, Hayashi K, et al. Uncultured adipose-derived regenerative cells promote
419 peripheral nerve regeneration. *J Orthop Sci* 2013;18:145-151.

420 32. Shoemaker SC, Rech H, Campbell P, Kram HB, Sanchez M. Effects of fibrin sealant on
421 incorporation of autograft and xenograft tendons within bone tunnels. A preliminary study. *Am*

422 *J Sports Med* 1989;17:318-324.

423

424 **Figure Legends**

425

426 **Fig 1.** The healing process between tendon graft and bone tissue after anterior cruciate ligament
427 reconstruction. Representative photomicrographs from the control limbs (upper row: A-E) and the
428 adipose-derived regenerative cell (ADRC)-treated limbs (lower row: F-J) at 2, 4, 6, 8, and 12 weeks
429 after surgery (hematoxylin and eosin, original magnification $\times 100$). The histological maturation at
430 the tendon-bone interface occurred earlier and was more improved in the ADRC-treated tissues
431 than that in the control tissues, especially in the early period after surgery. (B, bone; IF, interface; T,
432 tendon graft.)

433

434 **Fig 2.** Serial sections of an adipose-derived regenerative cell-treated limb showing (A) histology of
435 the tendon-bone interface at 2 weeks after surgery stained with hematoxylin and eosin (original
436 magnification $\times 40$) and (B) fluorescence microscopy for DiI. DiI-labeled cells at the tendon-bone
437 interface were observed under a fluorescent microscope using frozen tissue sections. Red
438 fluorescence indicating DiI-labeled cells was clearly visible on the tendon-bone interface at 2 weeks
439 after surgery (original magnification $\times 40$). (B, bone; IF, interface; T, tendon graft)

440

441 **Fig 3.** Biomechanical properties of the femur-graft-tibia complex after anterior cruciate ligament
442 (ACL) reconstruction. Bar charts showing the ultimate load at the point of failure of the
443 femur-graft-tibia complex at each time frame after ACL reconstruction in the control and
444 adipose-derived regenerative cell (ADRC)-treated groups ($*P < .05$). The ultimate failure load in the
445 ADRC-treated group was significantly greater than that in the control group at 2 and 4 weeks after
446 surgery ($P = .016$ and $P = .016$, respectively).

447

448 **Fig 4.** Bar charts showing the stiffness of the femur-graft-tibia complex at each time frame after
449 anterior cruciate ligament reconstruction in the control and adipose-derived regenerative cell
450 (ADRC)-treated groups ($*P < .05$). The stiffness in the ADRC-treated group was significantly higher

451 than that in the control group at 6 weeks after surgery ($P = .037$).

452

453 **Table 1.** Scoring System for Histological Examination

Histological features	Points
Graft remodeling	
None (0% of graft)	0
Slight (<10% of graft)	1
Fair (<25% of graft)	2
Moderate (<50% of graft)	3
Abundant ($\geq$ 50% of graft)	4
Interface connection / integration	
None	0
No directivity of collagen fiber	1
Appearance of directivity of collagen fiber	2
Appearance of fibrocartilaginous tissue	3
Appearance of mineralized cartilaginous tissue	4

454 NOTE. The maximum possible score is 8 points.

455

456 **Table 2.** Histological Scoring and Comparison between Groups

Time Point	ADRC-treated	Control	<i>P</i> value
2 wk	3.8 ± 0.7	2.3 ± 0.4	.005
4 wk	4.7 ± 0.4	3.1 ± 0.6	.005
6 wk	5.8 ± 0.4	3.6 ± 0.8	.005
8 wk	6.5 ± 0.5	5.8 ± 0.8	.093
12 wk	6.9 ± 0.7	6.3 ± 0.5	.149

457 NOTE. Data are given as mean ± standard deviation.

458